Tag: Sickle-Cell Anemia
Antibiotic Rx Adherence Varies Widely in Sickle Cell Care
Guideline-adherent therapy tied to fewer 30-day readmissions
FDA Approves Endari for the Treatment of Sickle Cell Disease
First treatment approved for patients with sickle cell disease in almost 20 years
Gene Therapy Described in a Patient With Sickle Cell Disease
But treatment has only been given to one patient so far
Sickle Cell Trait May Affect Reliability of HbA1c Readings
HbA1c levels significantly lower than in people without sickle cell trait
ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab
Lower rate of crises per year; longer median time to first, second crises with high-dose therapy
Sickle Cell Trait Doesn’t Up Mortality Risk in U.S. Soldiers
However, SC trait was linked with significantly higher risk of exertional rhabdomyolysis
ATS: Hydroxyurea Can Up Lung Function in Sickle Cell Disease
Drug slowed down the annual decline children had been showing before starting treatment
ASH: Prasugrel Doesn’t Cut Vaso-Occlusive Crisis in Sickle Cell
Rate of vaso-occlusive crisis events is not lower for children receiving prasugrel versus placebo
Hydroxyurea Underutilized for Patients With Sickle Cell
Only 23 percent using the drug within a year of their last pain crisis
